Indivior stock gains on solid analyst support and valuation
Published on 09/20/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior stock (ISIN GB00BYZ0C031) is trading near USD 34.88 as of September 20, 2026, positioning the specialty pharmaceuticals group at a mid-cap valuation with measurable upside versus analysts’ average 12-month target of around USD 45.17. According to MarketBeat on September 20, 2026, Indivior carries a consensus recommendation of Moderate Buy, with the average 1-year target price at USD 45.1667, implying a potential gain of roughly 29.6 percent from the current level.
Analysts see upside for Indivior
The analyst backdrop is a key driver for Indivior stock at the moment, because the spread between the current market price and consensus fair value is clearly positive. As MarketBeat reported on September 20, 2026, brokerages that have covered Indivior over the past year have set an average 12-month target of USD 45.1667, which is about USD 10.29 above the USD 34.88 opening level referenced in the same overview, highlighting a sizeable valuation gap in favor of long-term holders.
In addition to the traditional analyst consensus, quantitative valuation models also point to upside for Indivior stock. A healthcare sector screen by Faircurve on September 19, 2026 lists Indivior with a last close of USD 34.88, a model-derived fair value of USD 40.63 and a positive gap of 16.5 percent, classifying the shares as undervalued by that framework even though the verdict is accompanied by low model confidence.
Valuation and business context
The numbers from MarketBeat and Faircurve together frame Indivior as a specialty and generic drug manufacturer with room for appreciation, but also with risk factors investors need to monitor. According to Faircurve as of September 19, 2026, Indivior’s market value stands around USD 4.4 billion, which positions the company firmly in the mid-cap bracket compared with larger global pharma players and makes analyst coverage and model-based valuation particularly important for price discovery.
For investors, the combination of a roughly 29.6 percent upside to the average analyst target and a 16.5 percent discount to one model fair value figure is the core narrative at this stage. The analyst consensus captured by MarketBeat points to a supportive rating backdrop, while the Faircurve model assessment underlines that the stock still trades below one estimate of intrinsic value, even after taking into account the low confidence flag on that model.
Risk factors and upcoming checkpoints
The positive valuation picture is balanced by the usual risks for a specialty pharmaceuticals company, including potential litigation exposure in key markets, regulatory changes in the treatment of addiction and mental health, and competition from both branded and generic alternatives. While the analyst consensus at MarketBeat still classifies the stock as Moderate Buy, the presence of multiple rating opinions in that overview also suggests that not all analysts see the same degree of upside, underscoring the importance of upcoming fundamental data points.
From a medium-term perspective, upcoming quarterly results and any updates to guidance will be decisive for whether the valuation gap closes. While the sources at hand do not spell out a specific next earnings date for Indivior, the investor-relations overview at Indivior typically lists quarterly reporting dates and presentations that provide details on revenue growth, margins and cash generation, giving investors concrete metrics to compare against the USD 40.63 model fair value and the USD 45.1667 analyst average target appearing in the latest external analyses.
Indivior stock price and trading level
Indivior’s primary listing is on Nasdaq in the United States, where Indivior stock most recently opened at USD 34.88 according to MarketBeat on September 20, 2026. At that level, the shares trade below both the USD 40.63 model fair value highlighted by Faircurve as of September 19, 2026 and the USD 45.1667 average 1-year broker target, leaving the stock some distance from those reference points and emphasizing how future earnings releases and regulatory developments could influence whether that gap narrows or widens.
Indivior stock at a glance
- Company: Indivior PLC
- ISIN: GB00BYZ0C031
- Ticker: INDV
- Trading venue: Nasdaq
- Price (as of September 20, 2026): 34.88 USD
- Market capitalization: 4.4 billion USD (as of September 19, 2026)
- Sector / Industry: Healthcare / Specialty and generic pharmaceuticals
- Index membership: Not a member of a major headline index such as the S&P 500
